Date:11/2/2010

ur close collaboration with physicians, we have completed extensive development and testing of the new device and look forward to making this technology available to physicians and their patients in the near future.  We believe that Ventana will expand the EVAR market as it represents the first off-the-shelf solution to treat patients who otherwise have limited or no endovascular options. In combination with our recently announced acquisition of Nellix, Endologix will be able to treat the widest range of AAA anatomies, which further strengthens our position as an innovation leader in the marketplace."

About Endologix, Inc.Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

Forward-Looking Statements Except for historical information contained herein, this news release contains forward-looking statements, including the planned expansion of Endologix's product portfolio, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including the approval and success of sales efforts for new products, product research and development efforts, and other economic, business, co
'/>"/>

SOURCE Endologix, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Endologix to Acquire Nellix
2. Endologix Reports 30% Third Quarter 2010 Revenue Growth
3. Endologix to Present at Oppenheimer 21st Annual Healthcare Conference
4. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
5. Endologix to Report Third Quarter 2010 Financial Results on October 27, 2010
6. Endologix Receives CE Mark Approval for Expanded Line of Powerlink Products and PowerFit Aortic Extensions
7. Endologix Enters Development Agreement and Exclusive License for Balloon Expandable Stent Technology
8. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
9. Endologix Reports 47% Third Quarter 2009 Revenue Growth
10. Endologix to Report Third Quarter 2009 Financial Results on October 27, 2009
11. Endologix Responds to Alleged Patent Infringement